XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P XellSmart secures its fourth consecutive IND clearance from the US FDA and China's NMPA for a new cell therapy targeting MSA-P, showcasing its innovative approach.

XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P #China #Suzhou #XellSmart #iPSC_therapy #MSA-P

BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting BrainXell is set to showcase innovative findings on iPSC-derived therapies for Parkinson's Disease, focusing on BXT-110 during the 2025 SfN meeting in San Diego.

BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting #United_States #San_Diego #iPSC_therapy #BrainXell #BXT-110

XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials XellSmart's innovative allogeneic iPSC-derived cell therapy has received FDA approval for clinical trials, offering hope for spinal cord injury treatment.

XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials #China #Suzhou #Spinal_Cord_Injury #XellSmart #iPSC_therapy